Aptose Biosciences Inc. (APTOF)
OTCMKTS · Delayed Price · Currency is USD
1.230
0.00 (0.00%)
Aug 8, 2025, 4:00 PM EDT
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,641,000
Market Cap
3.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | -23 | -63.89% |
Dec 31, 2023 | 36 | 0 | - |
Dec 31, 2022 | 36 | -6 | -14.29% |
Dec 31, 2021 | 42 | 1 | 2.44% |
Dec 31, 2020 | 41 | 8 | 24.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
Spruce Biosciences | 21 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Aptose Biosciences News
- 3 days ago - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - GlobeNewsWire
- 8 days ago - Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - GlobeNewsWire
- 24 days ago - Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - GlobeNewsWire
- 5 weeks ago - Aptose Upgraded to Trade on OTCQB Market - GlobeNewsWire
- 5 weeks ago - Aptose Announces Deferral of Interest Payment - GlobeNewsWire
- 7 weeks ago - Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML - GlobeNewsWire
- 7 weeks ago - Aptose Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - GlobeNewsWire